Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
sunRIZE: RZ358 in Congenital Hyperinsulinism
NCT06208215Phase 3Active, not recruiting
- Sponsor
- Rezolute, Inc.
- Start
- Jan 2024
- Primary completion
- Nov 2025
- Modality
- Monoclonal Antibodies
- Countries
- 13
01
Overview
A Phase 3 trial of ersodetug in congenital hyperinsulinism (HI), sponsored by Rezolute, Inc.. Started Jan 2024; status: active, not recruiting.
02
Drugs
ersodetug
03
Conditions
congenital hyperinsulinism (HI)
Beyond the preview
Go deeper on NCT06208215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06208215.